These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 30191743)
1. Targeting of Influenza Viral Epitopes to Antigen-Presenting Cells by Genetically Engineered Chimeric Molecules in a Humanized NOD SCID Gamma Transfer Model. Ivanova II; Mihaylova NM; Manoylov IK; Makatsori D; Lolov S; Nikolova MH; Mamalaki A; Prechl J; Tchorbanov AI Hum Gene Ther; 2018 Sep; 29(9):1056-1070. PubMed ID: 30191743 [TBL] [Abstract][Full Text] [Related]
2. Built-in adjuvanticity of genetically and protein-engineered chimeric molecules for targeting of influenza A peptide epitopes. Kerekov NS; Ivanova II; Mihaylova NM; Nikolova M; Prechl J; Tchorbanov AI Immunol Res; 2014 Oct; 60(1):23-34. PubMed ID: 24515613 [TBL] [Abstract][Full Text] [Related]
3. DNA and protein-generated chimeric molecules for delivery of influenza viral epitopes in mouse and humanized NSG transfer models. Mihaylova NM; Manoylov IK; Nikolova MH; Prechl J; Tchorbanov AI Hum Vaccin Immunother; 2024 Dec; 20(1):2292381. PubMed ID: 38193304 [TBL] [Abstract][Full Text] [Related]
4. A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza. Andersen TK; Zhou F; Cox R; Bogen B; Grødeland G J Virol; 2017 Dec; 91(23):. PubMed ID: 28931687 [TBL] [Abstract][Full Text] [Related]
5. Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces long-lasting IgM and CTL responses to influenza virus. Ivanovska N; Tchorbanov A; Prechl J; Maximova V; Voynova E; Vassilev TL Vaccine; 2006 Mar; 24(11):1830-7. PubMed ID: 16289708 [TBL] [Abstract][Full Text] [Related]
6. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes. Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442 [TBL] [Abstract][Full Text] [Related]
7. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483 [TBL] [Abstract][Full Text] [Related]
8. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. Hillaire ML; Osterhaus AD; Rimmelzwaan GF J Biomed Biotechnol; 2011; 2011():939860. PubMed ID: 22007149 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. Abdel-Motal UM; Guay HM; Wigglesworth K; Welsh RM; Galili U J Virol; 2007 Sep; 81(17):9131-41. PubMed ID: 17609270 [TBL] [Abstract][Full Text] [Related]
10. Chimeric SV40 virus-like particles induce specific cytotoxicity and protective immunity against influenza A virus without the need of adjuvants. Kawano M; Morikawa K; Suda T; Ohno N; Matsushita S; Akatsuka T; Handa H; Matsui M Virology; 2014 Jan; 448():159-67. PubMed ID: 24314646 [TBL] [Abstract][Full Text] [Related]
11. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity. Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499 [TBL] [Abstract][Full Text] [Related]
12. Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection. Gilleland HE; Gilleland LB; Staczek J; Harty RN; García-Sastre A; Palese P; Brennan FR; Hamilton WD; Bendahmane M; Beachy RN FEMS Immunol Med Microbiol; 2000 Apr; 27(4):291-7. PubMed ID: 10727884 [TBL] [Abstract][Full Text] [Related]
13. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity. Ohba K; Yoshida S; Zahidunnabi Dewan M; Shimura H; Sakamaki N; Takeshita F; Yamamoto N; Okuda K Vaccine; 2007 May; 25(21):4291-300. PubMed ID: 17403560 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate. Kim MC; Lee YN; Kim YJ; Choi HJ; Kim KH; Lee YJ; Kang SM Antiviral Res; 2017 Dec; 148():43-52. PubMed ID: 29107058 [TBL] [Abstract][Full Text] [Related]
17. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice. Matsui M; Kohyama S; Suda T; Yokoyama S; Mori M; Kobayashi A; Taneichi M; Uchida T Biochem Biophys Res Commun; 2010 Jan; 391(3):1494-9. PubMed ID: 20060099 [TBL] [Abstract][Full Text] [Related]
18. Targeting of nucleoprotein to chemokine receptors by DNA vaccination results in increased CD8(+)-mediated cross protection against influenza. Baranowska M; Hauge AG; Hoornaert C; Bogen B; Grødeland G Vaccine; 2015 Dec; 33(49):6988-96. PubMed ID: 26387432 [TBL] [Abstract][Full Text] [Related]